Try our beta test site

Multicenter Trial of Daily Chlorhexidine Bathing to Reduce Nosocomial Infections (CBET)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2007 by Hunter Holmes Mcguire Veteran Affairs Medical Center.
Recruitment status was:  Recruiting
Centers for Disease Control and Prevention
Sage Products, Inc.
Information provided by:
Hunter Holmes Mcguire Veteran Affairs Medical Center Identifier:
First received: July 16, 2007
Last updated: August 6, 2007
Last verified: August 2007
To determine if daily bathing with chlorhexidine impregnated washcloths will reduce the incidence of MRSA and VRE within an Intensive Care Unit (ICU) or ward setting.

Condition Intervention
Nosocomial Bacteremia
MRSA Colonization
MRSA Infection
VRE Colonization
VRE Infection
Procedure: Bathing with Chlorhexidine Impregnated Washcloths

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE

Resource links provided by NLM:

Further study details as provided by Hunter Holmes Mcguire Veteran Affairs Medical Center:

Estimated Enrollment: 14000
Study Start Date: August 2007
Estimated Study Completion Date: September 2009
Detailed Description:
This is a cluster randomized, crossover-controlled trial with wards as the units of randomization. The trial will predominantly take place in ICU's but may include any acute care ward that has active surveillance for MRSA and or VRE in place (i.e., Bone Marrow transplant units, Oncology wards, etc.) Units will be randomly assigned to utilize two bathing routines in a random order. Each bathing routine will be utilized on all admitted patients to the unit for a six month study period for a total study duration of 12 months. The two bathing routines will include either the use of the Comfort® Bath Washcloth System (control) or the use of 2% Chlorhexidine Gluconate Cloth. Randomized units will either start with 2% Chlorhexidine Gluconate Cloth for six months and then switch to Comfort™ Bath Washcloth for the remaining six month period or the reverse order. Data collection will include all surveillance and clinical cultures for MRSA and or VRE and all bloodstream infections.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients admitted to study units during the proposed study interval are eligible for inclusion in the study

Exclusion Criteria:

  • Patients with known allergies to chlorhexidine gluconate or any other ingredients in the product
  • Patients with burns that include a high percentage of disrupted body surface area
  • Use in patients undergoing lumbar punctures or contact with the meninges
  • Patients with large open skin wounds; and
  • Children less than 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00502476

United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242-1081
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21205
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, Missouri
Barnes Jewish Hospital
St. Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
United States, Virginia
Hunter Holmes McGuire Veteran Affairs Medical Center
Richmond, Virginia, United States, 23249
Sponsors and Collaborators
Hunter Holmes Mcguire Veteran Affairs Medical Center
Centers for Disease Control and Prevention
Sage Products, Inc.
Study Director: Michael W Climo, MD Hunter Holmes Mcguire Veteran Affairs Medical Center
Principal Investigator: Edward S Wong, MD Hunter Holmes Mcguire Veteran Affairs Medical Center
Principal Investigator: Jane A Cecil, MD Hunter Holmes Mcguire Veteran Affairs Medical Center
Principal Investigator: Kent Sepkowitz, MD Weil Medical College of Cornell University
Principal Investigator: Trish M Perl, MD, MSc Johns Hopkins University
Principal Investigator: Debbie Yokoe, MD, MPH Harvard School of Medicine, Brigham and Women's Hospital
Principal Investigator: Maureen Bolon, MD Northwestern University Feinberg School of Medicine
Principal Investigator: Dave K Warren, MD Washington University School of Medicine
Principal Investigator: Loreen Herwaldt, MD University of Iowa
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00502476     History of Changes
Other Study ID Numbers: CI06-003 
Study First Received: July 16, 2007
Last Updated: August 6, 2007

Keywords provided by Hunter Holmes Mcguire Veteran Affairs Medical Center:

Additional relevant MeSH terms:
Communicable Diseases
Cross Infection
Bacterial Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Iatrogenic Disease
Disease Attributes
Chlorhexidine gluconate
Anti-Infective Agents, Local
Anti-Infective Agents
Dermatologic Agents processed this record on February 20, 2017